INDBInternet News Database 2.5 Updated 2 min ago · 414 sources Show or hide images Light or dark

Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer

1 source1 article First seen Updated United States

Save Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on third...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer

    (MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on third...